Stephane silvente 1.jpg

Stéphane SILVENTE

Chief  Executive Officer 

Stephane is an entrepreneur with 30+ years’ experience in building and managing dynamic teams. Stephane previously developed innovative technology in the Food Tech industry, generating several patents which were sold to Switzerland-based Nestlé. Afterwards Stephane founded Affichem, a France-based biotech company developing early-stage drug candidates in oncology, neurology and dermo-cosmetics. Stephane obtained a DESS degree from the University of Valenciennes, is also graduated from the EDC Business School in Paris and holds MBA from the Toulouse Business School.

F Thivet_edited.jpg

Frédéric THIVET

Chief  Financial Officer 

As an experienced lawyer and senior manager with track record in several law firms and companies during more than 20 years, Frederic developed skills in legal, finance, administration and HR. In 2005, he joined the biotech industry with Affichem as director in charge of legal, financial and administrative affairs. Frederic is graduated from the University of Toulouse 1 Capitole with a master’s degree in private and business law. He also obtained MBA from the Toulouse School of Management.

philippe-lefebvre_modifié.png

Philippe LEFEBVRE, MD, PhD

Chief  Scientific Officer 

Prof. Lefebvre graduated from the University of Liège (ULg) in 1987 and earned his title as doctor of biomedical science in 1991 after writing a paper on the neurobiology of the inner ear. That same year, he also obtained recognition as otolaryngology specialist. He completed a postdoctoral fellowship at the Albert Einstein College of Medicine in New York where he pursued his research on the neurobiology of the inner ear. In the US, he also acquired advanced skills in ear surgery. In 1997, he was appointed clinical professor at ULg. Since 2002, he is Professor of ENT at ULg and head of the ENT department. Prof. Lefebvre gained throughout his career a strong reputation in neurobiology of the inner ear and in pathophysiology of deafness.

Pierre_Attali_modifié.jpg

Pierre ATTALI, MD

Chief Medical Officer

Dr. Pierre Attali has over 30 years’ experience in global R&D in the life sciences industry. He previously led R&D teams at Synthelabo, Sanofi, BioAlliance, Onxeo and Sensorion. During his career, Dr. Attali was involved in the development and registration of several innovative drugs and he also contributed to several patent filings as well as publications of multiple articles in peer reviewed journals.

NICO NB.JPG

Nicolas CARON, PhD

Head of Preclinical Development

Nicolas started his career in the biotech industry with Affichem where he successfully managed several preclinical European and Regional R&D projects in hearing loss and neurology. Nicolas obtained a PhD in biomedical and pharmaceutical sciences at the University of Liège (ULg).

GS_edited.jpg

Gary SCHONBERG

Chief Business Development Officer

Over the last 10 years, Gary was involved or led many licensing, fundraising, equity capital markets and M&A deals in the life sciences industry. He held various business development roles at Uteron, Actavis and Mithra Pharmaceuticals. Gary also worked for ING investment banking, supporting notably the coverage of healthcare clients. He holds a master in engineering and business administration from the Solvay Business School in Brussels.

DSCF6422-w_modifié_edited.jpg

Arnaud RIVES, PhD

Chemistry Project manager

Arnaud was previously manager of Affichem's medicinal chemistry laboratory in France. He has 10 years’ experience in multi-step synthesis and implementation of optimization processes to produce bioactive molecules. Arnaud has been working on the optimization of the chemical synthesis for different dendrogenin-based molecules and developed a strong expertise in this field. He obtained a PhD in chemistry at the University of Toulouse.

QM_modifié.jpg

Quentin MARLIER, PhD

Biology Project manager

After obtaining his PhD in biomedical and pharmaceutical sciences at the University of Liège (ULg), Quentin completed his thesis at the GIGA on cell cycle dysregulation in central nervous system pathologies. He was later appointed lead manager biology at Dendrogenix.